Jones Financial Companies Lllp Buys 27,470 Shares of Novo Nordisk A/S (NYSE:NVO)

Jones Financial Companies Lllp grew its stake in Novo Nordisk A/S (NYSE:NVO) by 61.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,052 shares of the company’s stock after purchasing an additional 27,470 shares during the quarter. Jones Financial Companies Lllp’s holdings in Novo Nordisk A/S were worth $6,198,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. SRS Capital Advisors Inc. grew its stake in Novo Nordisk A/S by 119.6% in the 4th quarter. SRS Capital Advisors Inc. now owns 7,924 shares of the company’s stock valued at $682,000 after buying an additional 4,315 shares during the last quarter. Halbert Hargrove Global Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $47,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $107,000. Smartleaf Asset Management LLC increased its stake in shares of Novo Nordisk A/S by 88.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 17,788 shares of the company’s stock worth $1,525,000 after purchasing an additional 8,351 shares during the period. Finally, Tower View Wealth Management LLC lifted its holdings in Novo Nordisk A/S by 5.8% during the 4th quarter. Tower View Wealth Management LLC now owns 25,035 shares of the company’s stock worth $2,154,000 after purchasing an additional 1,379 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on NVO shares. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Price Performance

NVO stock opened at $89.42 on Tuesday. The company’s 50-day moving average price is $84.84 and its two-hundred day moving average price is $106.18. The firm has a market cap of $401.28 billion, a P/E ratio of 27.18, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12 month low of $77.82 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.